Other drug-induced secondary parkinsonism
ICD-10 G21.1 is a billable code used to indicate a diagnosis of other drug-induced secondary parkinsonism.
Other drug-induced secondary parkinsonism refers to a form of parkinsonism that arises as a consequence of exposure to certain medications, particularly those that affect dopaminergic pathways in the brain. This condition is characterized by symptoms similar to Parkinson's disease, including bradykinesia, rigidity, and tremors, but is distinct in that it is directly linked to pharmacological agents. Common culprits include antipsychotics, antiemetics, and certain antidepressants, which can induce extrapyramidal symptoms due to their dopamine-blocking effects. The onset of symptoms may occur shortly after starting the offending medication or increasing the dosage. Diagnosis typically involves a thorough medication history and clinical evaluation to rule out primary Parkinson's disease and other movement disorders. Management often includes discontinuation or adjustment of the offending drug, and in some cases, the use of anticholinergic medications or beta-blockers may be considered to alleviate symptoms. Understanding the relationship between drug exposure and parkinsonism is crucial for effective treatment and patient safety.
Detailed patient history, including medication use, symptom onset, and neurological examination findings.
Patients presenting with new-onset parkinsonism after starting antipsychotic medications.
Neurologists must ensure that all potential causes of parkinsonism are considered and documented.
Documentation of psychiatric medications prescribed, including dosages and duration of treatment.
Patients experiencing extrapyramidal symptoms after initiation of antipsychotic therapy.
Psychiatrists should monitor for movement disorders in patients on long-term antipsychotic therapy.
Used for follow-up visits of patients with drug-induced parkinsonism.
Document the patient's medication history and current symptoms.
Neurologists and psychiatrists should ensure comprehensive evaluations are documented.
Common medications include antipsychotics (e.g., haloperidol, risperidone), antiemetics (e.g., metoclopramide), and certain antidepressants that have dopaminergic effects.
